u/cloudy_vial_carol

discontinuation rate is a result, not a footnote

the actual decision rule is visual plus time. cloudy or particulate after it has had time to dissolve is a discard and not a debate. clear and inside its window is fine.

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

a fifteen-residue peptide is easy to make and easy to make badly

Most of what gets posted here is procedural rather than dramatic: a step skipped, a document not requested, a temperature not considered, a pace chosen out of impatience.

I would not archive earlier.

Adding the practical note — the formula is published and you can reproduce the ordering yourself.

Not convinced. Hypoglycaemia risk from this class alone is low; the risk you are describing comes from the combination.

Has anyone posted an independent result on that batch?

Which rule specifically, and which part of it?

Why comparing across trials almost never works, with the specific failure modes.

Different populations: an obesity programme and a diabetes programme enrol different people with different baseline characteristics. Different endpoints: body weight change, glycaemic control and cardiovascular events are not convertible. Different durations: 68 weeks and 72 weeks are not the same, and the curves have not flattened by either.

Different analysis populations: one paper reports intention-to-treat, another emphasises completers. Different support: some trial designs include structured lifestyle contact that no member of this board receives.

Stack those and the "X beats Y" tables that circulate here are comparing five things at once and attributing the difference to the molecule.

Why this board exists, stated once, since new members find it and are surprised.

Every other community surface on this site is a record of things that worked, because people post when they have something to show. That produces an archive with a systematic bias, and somebody at week three reads it and concludes that their difficult month is unusual.

This board is the counterweight. The rule is that nobody gets judged, that corrections stay up, and that the failures are written down with the same care as the successes. It is the least-visited part of the site and the part I would keep if I could only keep one.

Yes — nothing containing this is approved anywhere, and the threads keep forgetting it.

What else is in the regimen?

Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.

Why comparing across trials almost never works, with the specific failure modes.

Different populations: an obesity programme and a diabetes programme enrol different people with different baseline characteristics. Different endpoints: body weight change, glycaemic control and cardiovascular events are not convertible. Different durations: 68 weeks and 72 weeks are not the same, and the curves have not flattened by either.

Different analysis populations: one paper reports intention-to-treat, another emphasises completers. Different support: some trial designs include structured lifestyle contact that no member of this board receives.

Stack those and the "X beats Y" tables that circulate here are comparing five things at once and attributing the difference to the molecule.

somebody will read this at the point you were at, and it will help

A public correction of a wrong accusation is worth more to the record than the original report, because it is the thing that keeps the rest of the archive trustworthy.

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

identity, quantity, stability — three separate questions

Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering.

Right, and stopping for money reasons is not a failure of anything. It is a budget.

metformin and an incretin agonist are not in competition

What would the new rule do to the vendor evidence standard?

Why comparing across trials almost never works, with the specific failure modes.

Different populations: an obesity programme and a diabetes programme enrol different people with different baseline characteristics. Different endpoints: body weight change, glycaemic control and cardiovascular events are not convertible. Different durations: 68 weeks and 72 weeks are not the same, and the curves have not flattened by either.

Different analysis populations: one paper reports intention-to-treat, another emphasises completers. Different support: some trial designs include structured lifestyle contact that no member of this board receives.

Stack those and the "X beats Y" tables that circulate here are comparing five things at once and attributing the difference to the molecule.

Milligram comparisons across molecule classes are meaningless. Potency is a property of the molecule at its receptor, not of the number on the label.

modmail first, always, and the thread second

That is the 68-week readout, not the 72-week one. Different trial, different duration.

Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.

postprandial excursions are where most of the improvement shows up first

the fridge failure story happens every summer

Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.

Small correction — the shop in that story has no independent testing on file at all, which is different from having a bad record.

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

the human evidence is thin and the rodent evidence is not

I would not generalise from one bad month to a rule. The rest of your process sounds fine.

Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something.

Open-label extensions lose their randomisation.

This is the distinction that would end about half the arguments on this board.

check who the comparator was before you compare anything

The order things move in, since nobody explains it and it worries people.

Postprandial excursions generally respond earliest. Variability tends to narrow before the average does, which is visible on a sensor and invisible on a lab result. Fasting glucose is often the laggard, and A1c — being a three-month average — is the last thing to reflect anything.

So a month in which the sensor looks better and the fasting number has not moved is the ordinary sequence, not a contradiction. Knowing that in advance would have saved me a quarter of unnecessary worry, which is why it is worth writing down.